Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

References

• Kane JM. Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success. J Clin Psychiatry. 2013;74(9):e18. doi:10.4088/JCP.12117tx1c
   PubMedGoogle Scholar
• Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia–a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1–3):83–92. doi:10.1016/j.schres.2010.11.020
   PubMed Web of Science ®Google Scholar
• Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother. 2010;11(14):2301–2317. doi:10.1517/14656566.2010.499125
   PubMed Web of Science ®Google Scholar
• Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence. 2013;7:1171–1180. doi:10.2147/PPA.S53795
   PubMed Web of Science ®Google Scholar
• Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res. 2010;175(1–2):58–62. doi:10.1016/j.psychres.2008.11.003
   PubMed Web of Science ®Google Scholar
• Kirschner M, Theodoridou A, Fusar-Poli P, Kaiser S, Jager M. Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol. 2013;3(2):89–99. doi:10.1177/2045125312464106
   PubMedGoogle Scholar
• Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115(4):260–267. doi:10.1111/j.1600-0447.2006.00982.x
   PubMed Web of Science ®Google Scholar
• Olayinka O, Oyelakin A, Cherukupally K, et al. Use of long-acting injectable antipsychotic in an inpatient unit of a community teaching hospital. Psychiatry J. 2019;2019:8629030. doi:10.1155/2019/8629030
   Google Scholar
• Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 2004;30(2):255–264. doi:10.1093/oxfordjournals.schbul.a007076
   PubMed Web of Science ®Google Scholar
• Moritz S, Hunsche A, Lincoln TM. Nonadherence to antipsychotics: the role of positive attitudes towards positive symptoms. Eur Neuropsychopharmacol. 2014;24(11):1745–1752. doi:10.1016/j.euroneuro.2014.09.008
   PubMed Web of Science ®Google Scholar
• Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–468. doi:10.2147/PPA.S124658
   PubMed Web of Science ®Google Scholar
• Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30(8):689–701. doi:10.1007/s40263-016-0350-7
   PubMed Web of Science ®Google Scholar
• Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275–282. doi:10.1097/YIC.0b013e3280c28424
   PubMed Web of Science ®Google Scholar
• Bridges JF, Slawik L, Schmeding A, Reimer J, Naber D, Kuhnigk O. A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia. Health Expect. 2013;16(2):164–176. doi:10.1111/j.1369-7625.2011.00704.x
   PubMed Web of Science ®Google Scholar
• Bridges JF, Beusterien K, Heres S, et al. Quantifying the treatment goals of people recently diagnosed with schizophrenia using best-worst scaling. Patient Prefer Adherence. 2018;12:63–70. doi:10.2147/PPA.S152870
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19(7):7. doi:10.1093/ijnp/pyw018
   Web of Science ®Google Scholar
• Geerts P, Martinez G, Schreiner A. Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses. BMC Psychiatry. 2013;13(1):58. doi:10.1186/1471-244X-13-58
   Google Scholar
• Patel MX, Haddad PM, Chaudhry IB, McLoughlin S, Husain N, David AS. Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol. 2010;24(10):1473–1482. doi:10.1177/0269881109104882
   PubMed Web of Science ®Google Scholar
• Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives. Can J Psychiatry. 2013;58(5 Suppl 1):23S–29S. doi:10.1177/088740341305805s04
   Web of Science ®Google Scholar
• Gillespie M, Toner A. The safe administration of long-acting depot antipsychotics. Br J Nurs. 2013;22(8):464, 466–469. doi:10.12968/bjon.2013.22.8.464
   Google Scholar
• Quiroz JA, Rusch S, Thyssen A, Palumbo JM, Kushner S. Deltoid injections of risperidone long-acting injectable in patients with schizophrenia. Innov Clin Neurosci. 2011;8(6):20–28.
   Google Scholar
• Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):1022–1031. doi:10.1016/j.pnpbp.2009.05.014
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Papola D, Gastaldon C, Barbui C. New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base. Epidemiol Psychiatr Sci. 2017;26(3):231–233. doi:10.1017/S2045796016001025
   PubMed Web of Science ®Google Scholar
• Daghistani N, Rey JA. Invega trinza: the first four-times-a-year, long-acting injectable antipsychotic agent. P T. 2016;41(4):222–227.
   Google Scholar
• The American Psychiatric Association Practice Guideline for The Treatment of Patients with Schizophrenia. 2019.
   Google Scholar
• Aggarwal NK, Rosenheck RA, Woods SW, Sernyak MJ. Race and long-acting antipsychotic prescription at a community mental health center: a retrospective chart review. J Clin Psychiatry. 2012;73(4):513–517. doi:10.4088/JCP.11m07161
   PubMed Web of Science ®Google Scholar
• Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2–3):220–230. doi:10.1016/j.schres.2016.07.018
   PubMed Web of Science ®Google Scholar
• Ostuzzi G, Bighelli I, So R, Furukawa TA, Barbui C. Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies. Schizophr Res. 2017;183:10–21. doi:10.1016/j.schres.2016.11.010
   PubMed Web of Science ®Google Scholar